中国实用外科杂志

中国实用外科杂志

• 专题笔谈 • 上一篇    下一篇

分化型甲状腺癌术后131I治疗的规范化问题

陆汉魁   

  1. 上海交通大学附属第六人民医院核医学研究室，上海200233
  • 出版日期:2019-03-01 发布日期:2019-03-19

  • Online:2019-03-01 Published:2019-03-19

摘要：

分化型甲状腺癌（DTC）术后131I治疗的规范化是当前的趋势。由于DTC的一些临床特点、131I治疗的局限性以及不同临床研究结论的差异，选择131I治疗的具体指征存有争议。明确的治疗指征主要为手术不能切除的DTC转移灶，对术后未愈或未明确但疑似中高危DTC病人可采用131I辅助治疗。规范化诊疗的其他要求包括加强131I治疗期的辐射防护、客观细致的疗效评估及毒副反应的评估以及长期随访的数据管理。

关键词: 分化型甲状腺癌,  , 131I放射性同位素

Abstract:

Standardization of 131I treatment for patients with differentiated thyroid cancers after thyroidectomy        LU Han-kui. Department of Nuclear Medicine, Shanghai Sixth Hospital of Shanghai Jiaotong University, Shanghai 201101，China
Abstract    Standardization of 131I treatment following thyroidectomy for DTC patients tends to be compulsory in clinical practice. However，many remains controversies concerning with the indications for 131I treatment since it takes definitive effects mostly in parts of DTC patients with unresectable lesions or metastases. Standardization of 131I treatment also requires proper management of radiation protection for in-patients taking high dose 131I，objective and complete evaluation of treatment outcomes as well as side effects related with 131I therapy，and above all，the establishment of long-term follow-up database.

Key words: differentiated thyroid cancer, radioisotope 131I